Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SpyGlass Unveils Data of Its Drug Delivery Platform Implanted During Cataract Surgery
Details : SpyGlass platform is - bimatoprost implanted with the SpyGlass intraocular lens (IOL) which is designed to deliver three years of bimatoprost sustained delivery for glaucoma management.
Brand Name : SpyGlass IOL
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 02, 2024
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SpyGlass Pharma Initiates Phase I/II Clinical Trial of its Intraocular Drug Delivery Platform
Details : SpyGlass platform is - bimatoprost implanted with the SpyGlass intraocular lens (IOL) which is designed to deliver three years of bimatoprost sustained delivery for glaucoma management.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 31, 2023
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Study Phase : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $90.0 million
Deal Type : Series C Financing
Details : The financing will be used to advance novel treatments for glaucoma and other chronic ophthalmic diseases, including Bimatoprost, a prostaglandin analogue.
Brand Name : Undislosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 10, 2023
Lead Product(s) : Bimatoprost
Therapeutic Area : Ophthalmology
Highest Development Status : Phase I/ Phase II
Sponsor : RA Capital Management
Deal Size : $90.0 million
Deal Type : Series C Financing
LOOKING FOR A SUPPLIER?